Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment of hypertension,Management of angina pectoris (chronic stable, vasospastic, unstable),Rate control in atrial fibrillation/flutter,Supraventricular tachyarrhythmias
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
3-4.5 hours; prolonged in hepatic impairment (up to 10 hours) and in elderly
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Extensively metabolized in the liver via CYP3A4; undergoes deacetylation, N-demethylation, and O-demethylation; metabolites include desacetyl-diltiazem (active).
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: 2-4% unchanged; hepatic metabolism with biliary excretion; fecal elimination accounts for ~10%
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
70-80% bound to albumin
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
5-8 L/kg; indicates extensive tissue binding
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: ~40-50% due to first-pass metabolism; IV: 100%
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No adjustment required for GFR >10 m L/min; for GFR <10 m L/min, use with caution and monitor heart rate.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh Class A: reduce dose to 5-10 mg/hour; Child-Pugh Class B: reduce to 2.5-5 mg/hour; Child-Pugh Class C: avoid use.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Children: 0.25-0.33 mg/kg/hour continuous IV infusion; maximum 15 mg/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Elderly: initial dose at lower end of range (5-10 mg/hour); titrate slowly due to increased sensitivity and risk of bradycardia.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
There is no FDA black box warning for diltiazem.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
May cause bradycardia and AV block,Concomitant use with beta-blockers increases risk of bradycardia/heart failure,Avoid in patients with left ventricular dysfunction,May worsen heart failure in patients with reduced ejection fraction,Hepatic impairment requires dose adjustment,Monitor renal function in elderly; may cause hypotension,Avoid abrupt withdrawal
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Sick sinus syndrome (except with pacemaker),Second- or third-degree AV block (except with pacemaker),Severe hypotension (systolic <90 mm Hg),Acute myocardial infarction with pulmonary congestion,Hypersensitivity to diltiazem,Concurrent use with ivabradine
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid consumption of grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing diltiazem serum concentrations and risk of toxicity. No other significant food interactions.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
No adequate studies in pregnant women. In animal studies, diltiazem has been associated with embryofetal toxicity (skeletal abnormalities, increased mortality) at doses >5 times the maximum recommended human dose. Use only if potential benefit justifies risk. First trimester: potential teratogen, avoid unless essential. Second and third trimesters: may cause uterine hypoperfusion and fetal hypoxia due to maternal hypotension; monitor fetal heart rate and uterine activity if used near term.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Diltiazem is excreted into human milk; milk-to-plasma ratio approximately 0.9. Limited data suggest low levels but potential for adverse effects in nursing infants (bradycardia, hypotension). Consider alternatives, especially while nursing a preterm or low-birth-weight infant. If used, monitor infant for signs of bradycardia and hypotension.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance. No established dose adjustment guidelines; use lowest effective dose. Monitor clinical response and titrate cautiously. Consider starting at lower-end doses (e.g., 30 mg PO QID) and increase based on BP and HR. IV use may require more careful titration due to volume changes.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Diltiazem hydrochloride in 0.72% sodium chloride is an intravenous calcium channel blocker used for rate control in atrial fibrillation/flutter and hypertension. Monitor heart rate and blood pressure closely; may cause bradycardia, hypotension, and heart block. Avoid in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. The 0.72% sodium chloride concentration provides isotonicity; ensure proper IV access to prevent extravasation tissue necrosis. Contraindicated with concurrent beta-blocker use due to additive bradycardic effects.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication is given intravenously to control heart rate or lower blood pressure.,You will have your heart rate and blood pressure monitored continuously during infusion.,Report symptoms of dizziness, fainting, slow heart rate, or difficulty breathing.,Avoid grapefruit juice as it may increase drug levels and side effects.,Do not stop taking other heart medications without consulting your doctor.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Mebendazole, an anthelmintic, inhibits CYP3A4-mediated metabolism of diltiazem, a calcium channel blocker used for hypertension and angina. This results in elevated diltiazem plasma concentrations, increasing the risk of bradycardia, hypotension, and atrioventricular block. Patients may experience enhanced negative chronotropic effects, leading to symptomatic bradycardia or heart block."
"Antipyrine, a substrate of cytochrome P450 (CYP) 3A4, when coadministered with Diltiazem, a moderate inhibitor of CYP3A4, results in decreased metabolic clearance of Diltiazem. This leads to increased plasma concentrations of Diltiazem, potentiating its negative chronotropic and hypotensive effects. Clinically, this interaction may manifest as bradycardia, atrioventricular block, and excessive hypotension."
"Diltiazem, a moderate CYP3A4 inhibitor, can significantly increase the systemic exposure of ceritinib, a sensitive CYP3A4 substrate. This interaction leads to elevated ceritinib plasma concentrations, potentiating its dose-dependent toxicities, including hepatotoxicity, QT interval prolongation, and gastrointestinal disturbances. Concomitant use may require ceritinib dose reduction or temporary discontinuation to mitigate adverse effects."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is a Electrolyte that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is: Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The metabolism of Diltiazem can be decreased when combined with Aminophylline. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is classified as Category A/B. No adequate studies in pregnant women. In animal studies, diltiazem has been associated with embryofetal toxicity (skeletal abnormalities, increased mortality) at doses >5 times th. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.